The diagnosis and the treatment of dominant strictures (DS) in patients with primary sclerosing cholangitis (PSC) is challenging and the scientific literature on the subject is quite limited. Only level II and level III evidence is available to guide physicians managing patients with DS and PSC. For the diagnosis, intraductal endoscopic ultrasound is the most sensitive (64%) and specific (95%) test. However, the majority of cases require a combination of several different diagnostic tests, as there is no single investigation that can rule out malignancy in this group of patients. For the treatment, serial endoscopic or percutaneous dilatations provide 1- and 3-year biliary duct patency in 80 and 60% of patients, respectively. Dilatation and stenting are the most common interventions, although the optimal duration of treatment has still not been clearly defined. Bile duct resection and/or bilioenteric bypass are currently indicated only for patients with preserved liver function. For all other patients, benign DS can be treated with endoscopic dilatation with short-term stenting. This approach is effective and safe and does not increase the risk of malignant transformation or complications for liver transplant candidates. During the last decade, the use of self-expandable metallic stents for benign diseases has become an innovative option. The aim of this article is to review the diagnostic and therapeutic strategies for patients affected by PSC and DS with specific emphasis on the outcomes of patients treated with temporary stents.

1.
Lee YM, Kaplan MM: Primary sclerosing cholangitis. N Engl J Med 1995;332:924-933.
2.
Nakanuma Y, Hirai N, Kono N, Ohta G: Histological and ultrastructural examination of the intrahepatic biliary tree in primary sclerosing cholangitis. Liver 1986;6:317-325.
3.
Broome U, Grunewald J, Scheynius A, et al: Preferential V beta3 usage by hepatic T lymphocytes in patients with primary sclerosing cholangitis. J Hepatol 1997;26:527-534.
4.
Bambha K, Kim WR, Talwalkar J, et al: Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:1364-1369.
5.
Boberg KM, Aadland E, Jahnsen J, et al: Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99-103.
6.
Kingham JG, Kochar N, Gravenor MB: Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004;126:1929-1930.
7.
Smith T, Befeler AS: High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Curr Gastroenterol Rep 2007;9:54-59.
8.
Charatcharoenwitthaya P, Lindor KD: Primary sclerosing cholangitis: diagnosis and management. Curr Gastroenterol Rep 2006;8:75-82.
9.
Fickert P, Wagner M, Marschall HU, et al: 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006;130:465-481.
10.
Beuers U, Spengler U, Kruis W, et al: Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16:707-714.
11.
Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-695.
12.
van Hoogstraten HJ, Vleggaar FP, Boland GJ, et al: Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 2000;95:2015-2022.
13.
Vacca M, Krawczyk M, Petruzzelli M, et al: Current treatments of primary sclerosing cholangitis. Curr Med Chem 2007;14:2081-2094.
14.
Ishibashi H, Komori A, Shimoda S, Gershwin ME: Guidelines for therapy of autoimmune liver disease. Semin Liver Dis 2007;27:214-226.
15.
Stiehl A: Primary sclerosing cholangitis: the role of endoscopic therapy. Semin Liver Dis 2006;26:62-68.
16.
Stiehl A, Rost D: Endoscopic treatment of dominant stenoses in patients with primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005;28:159-165.
17.
Yamamoto T, Hirohashi K, Kubo S, et al: Surgery for segmental primary sclerosing cholangitis. Hepatogastroenterology 2004;51:668-671.
18.
Hirai I, Ishiyama S, Fuse A, et al: Primary sclerosing cholangitis successfully treated by resection of the confluence of the hepatic duct. J Hepatobiliary Pancreat Surg 2001;8:169-173.
19.
Ahrendt SA, Pitt HA, Kalloo AN, et al: Primary sclerosing cholangitis: resect, dilate, or transplant? Ann Surg 1998;227:412-423.
20.
Van Laethem JL, Deviere J, Bourgeois N, et al: Cholangiographic findings in deteriorating primary sclerosing cholangitis. Endoscopy 1995;27:223-228.
21.
Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R: Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004;99:502-508.
22.
Gossard AA, Angulo P, Lindor KD: Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol 2005;100:1330-1333.
23.
Olsson R, Boberg KM, de Muckadell OS, et al: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-1472.
24.
LaRusso NF, Shneider BL, Black D, et al: Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006;44:746-764.
25.
Ponsioen CY, Lam K, van Milligen de Wit AW, et al: Four years' experience with short-term stenting in primary sclerosing cholangitis. Am J Gastroenterol 1999;94:2403-2407.
26.
Stiehl A, Rudolph G, Kloters-Plachky P, et al: Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002;36:151-156.
27.
van Milligen de Wit AW, van Bracht J, Rauws EA, et al: Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1996;44:293-299.
28.
Olsson RG, Asztely MS: Prognostic value of cholangiography in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 1995;7:251-254.
29.
MacCarty RL, LaRusso NF, Wiesner RH, Ludwig J: Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 1983;149:39-44.
30.
May GR, Bender CE, LaRusso NF, Wiesner RH: Nonoperative dilatation of dominant strictures in primary sclerosing cholangitis. AJR Am J Roentgenol 1985;145:1061-1064.
31.
Tischendorf JJ, Kruger M, Trautwein C, et al: Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy 2006;38:665-669.
32.
Bergquist A, Broome U: Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001;15:643-656.
33.
Farrant JM, Hayllar KM, Wilkinson ML, et al: Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991;100:1710-1717.
34.
Kaya M, de Groen PC, Angulo P, et al: Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. Am J Gastroenterol 2001;96:1164-1169.
35.
Rosen CB, Nagorney DM, Wiesner RH, et al: Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991;213:21-25.
36.
Pohl J, Ring A, Stremmel W, Stiehl A: The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2006;18:69-74.
37.
Lee JG, Schutz SM, England RE, et al: Endoscopic therapy of sclerosing cholangitis. Hepatology 1995;21:661-667.
38.
Bjornsson E, Boberg KM, Cullen S, et al: Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002;51:731-735.
39.
Macchi V, Floreani A, Marchesi P, et al: Imaging of primary sclerosing cholangitis: preliminary results by two new non-invasive techniques. Dig Liver Dis 2004;36:614-621.
40.
Schulte SJ, Baron RL, Teefey SA, et al: CT of the extrahepatic bile ducts: wall thickness and contrast enhancement in normal and abnormal ducts. AJR Am J Roentgenol 1990;154:79-85.
41.
Eracleous E, Genagritis M, Papanikolaou N, et al: Complementary role of helical CT cholangiography to MR cholangiography in the evaluation of biliary function and kinetics. Eur Radiol 2005;15:2130-2139.
42.
Silverman W: Complication rate of endoscopic retrograde cholangiopancreatography (ERCP) in patients with primary sclerosing cholangitis (PSC): is it safe? Gastroenterology 1994;106:A359.
43.
Moff SL, Kamel IR, Eustace J, et al: Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 2006;64:219-223.
44.
van den Hazel SJ, Wolfhagen EH, van Buuren HR, et al: Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy 2000;32:779-782.
45.
Harbin WP, Mueller PR, Ferrucci JT Jr: Transhepatic cholangiography: complications and use patterns of the fine-needle technique: a multi-institutional survey. Radiology 1980;135:15-22.
46.
Cohen SA, Siegel JH, Kasmin FE: Complications of diagnostic and therapeutic ERCP. Abdom Imaging 1996;21:385-394.
47.
Berstad AE, Aabakken L, Smith HJ, et al: Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2006;4:514-520.
48.
Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW, et al: Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 1999;31:305-309.
49.
Boberg KM, Jebsen P, Clausen OP, et al: Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006;45:568-574.
50.
Ahrendt SA, Pitt HA, Nakeeb A, et al: Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Surg 1999;3:357-367.
51.
Vera A, Moledina S, Gunson B, et al: Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002;360:1943-1944.
52.
Sebo TJ: Digital image analysis. Mayo Clin Proc 1995;70:81-82.
53.
Persons DL, Takai K, Gibney DJ, et al: Comparison of fluorescence in situ hybridization with flow cytometry and static image analysis in ploidy analysis of paraffin-embedded prostate adenocarcinoma. Hum Pathol 1994;25:678-683.
54.
Moreno Luna LE, Kipp B, Halling KC, et al: Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006;131:1064-1072.
55.
Graziadei IW, Wiesner RH, Marotta PJ, et al: Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999;30:1121-1127.
56.
Dickson ER, Murtaugh PA, Wiesner RH, et al: Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992;103:1893-1901.
57.
Baluyut AR, Sherman S, Lehman GA, et al: Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001;53:308-312.
58.
Gotthardt DN, Rudolph G, Kloters-Plachky P, et al: Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointest Endosc 2010;71:527-534.
59.
Kaya M, Petersen BT, Angulo P, et al: Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1059-1066.
60.
Angulo P, Lindor KD: Primary sclerosing cholangitis: emerging new promising therapies. J Clin Gastroenterol 2000;31:271-273.
61.
Raijman I: Biliary and pancreatic stents. Gastrointest Endosc Clin N Am 2003;13:561-592.
62.
Khashab MA, Kim K, Hutfless S, et al: Predictors of early stent occlusion among plastic biliary stents. Dig Dis Sci 2012;57:2446-2450.
63.
van Berkel AM, van Marle J, van Veen H, et al: A scanning electron microscopic study of biliary stent materials. Gastrointest Endosc 2000;51:19-22.
64.
Costamagna G, Mutignani M, Rotondano G, et al: Hydrophilic hydromer-coated polyurethane stents versus uncoated stents in malignant biliary obstruction: a randomized trial. Gastrointest Endosc 2000;51:8-11.
65.
Nakamura S, Ohara H, Yamada T, et al: Efficacy of plastic tube stents without side holes for middle and lower biliary strictures. J Clin Gastroenterol 2002;34:77-80.
66.
Costamagna G, Pandolfi M, Mutignani M, et al: Long-term results of endoscopic management of postoperative bile duct strictures with increasing numbers of stents. Gastrointest Endosc 2001;54:162-168.
67.
Draganov P, Hoffman B, Marsh W, et al: Long-term outcome in patients with benign biliary strictures treated endoscopically with multiple stents. Gastrointest Endosc 2002;55:680-686.
68.
Perri V, Familiari P, Tringali A, et al: Plastic biliary stents for benign biliary diseases. Gastrointest Endosc Clin N Am 2011;21:405-433.
69.
Pausawasadi N, Soontornmanokul T, Rerknimitr R: Role of fully covered self-expandable metal stent for treatment of benign biliary strictures and bile leaks. Korean J Radiol 2012;13(suppl 1):S67-S73.
70.
Srinivasan I, Kahaleh M: Biliary stents in the millennium. Adv Ther 2011;28:960-972.
71.
Cantu P, Hookey LC, Morales A, et al: The treatment of patients with symptomatic common bile duct stenosis secondary to chronic pancreatitis using partially covered metal stents: a pilot study. Endoscopy 2005;37:735-739.
72.
Foerster EC, Hoepffner N, Domschke W: Bridging of benign choledochal stenoses by endoscopic retrograde implantation of mesh stents. Endoscopy 1991;23:133-135.
73.
O'Brien SM, Hatfield AR, Craig PI, Williams SP: A 5-year follow-up of self-expanding metal stents in the endoscopic management of patients with benign bile duct strictures. Eur J Gastroenterol Hepatol 1998;10:141-145.
74.
Dumonceau JM, Nicaise N, Deviere J: The ultraflex diamond stent for benign biliary obstruction. Gastrointest Endosc Clin N Am 1999;9:541-545.
75.
Kahaleh M, Tokar J, Le T, Yeaton P: Removal of self-expandable metallic Wallstents. Gastrointest Endosc 2004;60:640-644.
76.
Shin HP, Kim MH, Jung SW, et al: Endoscopic removal of biliary self-expandable metallic stents: a prospective study. Endoscopy 2006;38:1250-1255.
77.
Kahaleh M, Behm B, Clarke BW, et al: Temporary placement of covered self-expandable metal stents in benign biliary strictures: a new paradigm? (with video). Gastrointest Endosc 2008;67:446-454.
78.
Mahajan A, Ho H, Sauer B, et al: Temporary placement of fully covered self-expandable metal stents in benign biliary strictures: midterm evaluation (with video). Gastrointest Endosc 2009;70:303-309.
79.
Sauer BG, Regan KA, Srinivasan I, Shami VM, Rehan ME, Ellen K: Temporary placement of covered self-expandable metal stents (CSEMS) in benign biliary strictures (BBS): eight years of experience. Gastrointest Endosc 2010;71:110-111.
80.
Cote GA, Kumar N, Ansstas M, et al: Risk of post-ERCP pancreatitis with placement of self-expandable metallic stents. Gastrointest Endosc 2010;72:748-754.
81.
Ho H, Mahajan A, Gosain S, et al: Management of complications associated with partially covered biliary metal stents. Dig Dis Sci 2010;55:516-522.
82.
Bezzi M, Zolovkins A, Cantisani V, et al: New ePTFE/FEP-covered stent in the palliative treatment of malignant biliary obstruction. J Vasc Interv Radiol 2002;13:581-589.
83.
Hausegger KA, Thurnher S, Bodendorfer G, et al: Treatment of malignant biliary obstruction with polyurethane-covered Wallstents. AJR Am J Roentgenol 1998;170:403-408.
84.
Park do H, Lee SS, Lee TH, et al: Anchoring flap versus flared end, fully covered self-expandable metal stents to prevent migration in patients with benign biliary strictures: a multicenter, prospective, comparative pilot study (with videos). Gastrointest Endosc 2011;73:64-70.
85.
Hwang JC, Kim JH, Yoo BM, et al: Temporary placement of a newly designed, fully covered, self-expandable metal stent for refractory bile leaks. Gut Liver 2011;5:96-99.
86.
Skolkin MD, Alspaugh JP, Casarella WJ, et al: Sclerosing cholangitis: palliation with percutaneous cholangioplasty. Radiology 1989;170:199-206.
87.
UNOS: http://www.unos.org (accessed February 29, 2008).
88.
Ahrendt SA: Surgical approaches to strictures in primary sclerosing cholangitis. J Gastrointest Surg 2008;12:423-425.
89.
Tsai S, Pawlik TM: Primary sclerosing cholangitis: the role of extrahepatic biliary resection. Adv Surg 2009;43:175-188.
90.
van Boeckel PG, Vleggaar FP, Siersema PD: Plastic or metal stents for benign extrahepatic biliary strictures: a systematic review. BMC Gastroenterol 2009;9:96.
91.
Levy MJ, Baron TH, Clayton AC, et al: Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol 2008;103:1263-1273.
92.
Nakeeb A, Lipsett PA, Lillemoe KD, et al: Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg 1996;171:147-152.
93.
Majoie CB, Smits NJ, Phoa SS, et al: Primary sclerosing cholangitis: sonographic findings. Abdom Imaging 1995;20:109-112.
94.
Silverman WB, Kaw M, Rabinovitz M, Schade RR, Bates BL: Complication rate of endoscopic retrograde cholangiopancreatography (ERCP) in patients with primary sclerosing cholangitis (PSC): is it safe? Gastroenterology 1994;106:359.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.